nivolumab,ipilimumab
bms
['lung', 'nivolumab', 'nsclc', 'check,mate,9la', 'ipilimumab', 'nivo', 'lcsm,(-blcsm)', '9la', 'sclc']
#asco23 #lungcancer #lcsm first-line (1l) nivolumab (n) + ipilimumab (i) + chemotherapy (c) vs c alone in patients with metastatic nsclc (mnsclc) from checkmate 9la: 4 y clinical update &amp; outcomes by tumor histologic subtype (ths). abstract: lba9023 | pstr bd #: 11 
Working to improve and save lives by funding groundbreaking research for the prevention, diagnosis, treatment and cure of lung cancer.